Listen to the article
In a significant legal challenge, Eli Lilly and Co. has petitioned the U.S. Supreme Court to strike down a key provision of the False Claims Act, a law dating back to the Civil War era that allows private whistleblowers to sue for fraud on behalf of the federal government.
The Indianapolis-based pharmaceutical giant is contesting a $183.7 million judgment stemming from a case brought by pharmacist Ronald J. Streck, who alleged the company made false claims regarding rebates to the federal Medicaid program. Lilly’s petition, filed Thursday, specifically targets the “qui tam” provision of the act, arguing it violates the separation of powers outlined in Article II of the U.S. Constitution.
In its filing, Lilly described whistleblowers as “bounty hunters” and “vigilantes” who wield too much authority without accountability to the U.S. president. “The Constitution does not permit prosecution by private vigilantes,” Lilly asserted in its petition. “Nor does it allow regulation by hindsight.”
The False Claims Act, also known as the Lincoln Law, was originally enacted in 1863 to combat defense contractor fraud during the Civil War. Congress substantially strengthened the law in 1986, creating a powerful mechanism for private citizens to sue individuals or companies defrauding the government and recover damages on the government’s behalf. Whistleblowers who bring successful qui tam cases can receive rewards of 15% to 30% of the government’s recovery.
The act has become a significant tool for federal fraud enforcement. According to the U.S. Department of Justice, settlements and judgments under the False Claims Act reached a historic high of $6.8 billion in 2025. Whistleblowers filed 1,297 qui tam lawsuits that year—the highest number ever recorded—and the government opened 401 investigations. Since the 1986 amendments, total settlements and judgments have exceeded $85 billion.
Lilly’s challenge comes at a time when several Supreme Court justices have signaled willingness to reconsider the qui tam provision’s constitutionality. Last year, Justices Clarence Thomas, Brett Kavanaugh, and Amy Coney Barrett indicated they would entertain constitutional challenges to this aspect of the law. For the Supreme Court to hear a petition, four justices must agree to bring the case before the full court.
The case against Lilly originated with Streck, a former executive of a national network of regional drug wholesalers. In 2023, U.S. District Judge Harry D. Leinenweber in Illinois tripled the damages in a jury verdict against the company, resulting in the $183.7 million judgment. The judge determined Lilly was liable for higher payments due to its conduct and applicable federal penalty laws.
Streck and his legal team argued that Lilly engaged in systematic misconduct over more than a decade, from 2005 to 2017, by miscalculating drug rebates under the Medicaid program. Specifically, they alleged the company left retroactive drug price increases out of its calculations.
In February 2022, Judge Leinenweber ruled that Streck’s legal team had successfully established that Lilly made false statements to the Centers for Medicare and Medicaid Services about prices charged to distributors for its drugs. A federal jury subsequently found 43 federal violations before November 2015 and nine violations afterward, initially ordering Lilly to pay $61 million in damages before the judge’s tripling of the award.
This case represents just one in a series of successful False Claims Act lawsuits brought by Streck against pharmaceutical manufacturers for alleged misconduct involving the Medicaid Drug Rebate Program. His previous legal actions have resulted in significant settlements, including $75 million from Bristol Myers Squibb and $18 million from Astellas Pharma U.S.
The outcome of Lilly’s Supreme Court petition could have far-reaching implications for whistleblower litigation and corporate accountability in cases involving government programs. If successful, it would fundamentally alter a longstanding mechanism for detecting and prosecuting fraud against the federal government.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
14 Comments
This case gets to the heart of balancing whistleblower empowerment and proper government oversight. Eli Lilly makes some compelling arguments about the False Claims Act’s qui tam provision, but the law has also served an important purpose. It will be fascinating to see how the Supreme Court navigates these complex constitutional questions.
Exactly. There are valid concerns on both sides that the Supreme Court will need to carefully weigh. Their ruling could have significant ramifications for how the False Claims Act is applied going forward.
The False Claims Act dates back to the Civil War era, so it will be interesting to see how the Supreme Court views its constitutionality in the modern context. Eli Lilly’s arguments about private ‘bounty hunters’ wielding too much power seem worth considering, but the law has also served an important purpose over the decades.
Absolutely, the historical context is relevant here. The False Claims Act was created for a specific purpose, but its application has evolved over time. The Supreme Court will have to weigh its continued value against the constitutional questions raised.
The False Claims Act has been a valuable tool, but Eli Lilly raises legitimate constitutional questions about the qui tam provision empowering private ‘bounty hunters.’ The Supreme Court will have to find the right balance between combating fraud and maintaining proper government oversight. It’s a complex issue without easy answers.
This is an interesting legal challenge to the False Claims Act. The qui tam provision does seem to give a lot of power to private whistleblowers, though it’s also important to have ways to uncover fraud against the government. It will be worth following how the Supreme Court rules on the constitutional questions raised.
I agree, the balance between empowering whistleblowers and maintaining proper government oversight is tricky. The Supreme Court will have to carefully consider the arguments on both sides.
This is a high-stakes case that could have major implications for how the False Claims Act is applied going forward. Eli Lilly is taking on a long-standing law, so the Supreme Court’s ruling will be closely watched. It’s a complex issue without easy answers.
Challenging the constitutionality of the False Claims Act’s qui tam provision is a bold move by Eli Lilly. The law has been used to uncover a lot of fraud, but the company raises valid concerns about private citizens wielding too much unchecked power. The Supreme Court’s decision will be highly influential.
The False Claims Act has been an important tool for uncovering fraud, but Eli Lilly raises valid concerns about the limits of private enforcement. The Supreme Court will have to carefully balance the law’s benefits and risks. It will be interesting to see how they rule on the constitutional questions involved.
Well said. The Supreme Court will need to weigh the law’s historical purpose and practical application against the separation of powers issues raised by Eli Lilly. It’s a nuanced case with far-reaching implications.
As a pharmaceutical company, Eli Lilly likely has concerns about the False Claims Act being used to target them. However, the qui tam provision has played an important role in identifying fraud, so the Supreme Court will need to balance those competing interests. It’s a complex issue without easy answers.
Eli Lilly is arguing that the False Claims Act’s qui tam provision gives too much authority to private citizens without proper accountability. It’s an interesting constitutional challenge, as the law has been an important tool for uncovering fraud for over 150 years. The outcome could have significant implications.
You raise a good point. The False Claims Act has been used to uncover a lot of fraud, but the limits of private enforcement are worth examining. The Supreme Court will have to weigh the benefits and risks carefully.